Flow Cytometry
Customize your policy alerts
Sign up for Capital Bluecross Policy AHS - F2019 - Flow Cytometry alerts
Get alerted when Policy AHS - F2019 - Flow Cytometry changes without checking for updates manually.
Monitor payer policy activity
Defines coverage, reimbursement limitations, and clinical indications for flow cytometry testing for Capital Bluecross members, including which flow cytometry uses meet or do not meet coverage criteria and coding/reimbursement rules.
No material clinical or coverage changes in this revision.
Coverage Criteria for Flow Cytometry
inv-01: Flow cytometry coverage criteria
Covered when ALL of the following are met:
Indications (ONE or more)
- Cytopenias, lymphomas, leukemia, myeloproliferative and lymphoproliferative disorders, or myelodysplastic syndrome.
- B‑cell monitoring for immunosuppressive disorders.
- T‑cell monitoring for HIV infection and AIDS.
- Mast cell neoplasms.
- Paroxysmal nocturnal hemoglobinuria (PNH).
- Preoperative or postoperative monitoring of individuals undergoing organ transplantation (pre/post transplant monitoring).
- Plasma cell disorders (eg, suspected/plasma cell neoplasia or monoclonal gammopathy requiring immunophenotyping).
- Primary immunodeficiencies (PIDs) for diagnosis or monitoring.
- Primary platelet disorders (non‑neoplastic) and other platelet function/number disorders where flow cytometry is indicated.
- Red cell and white cell disorders (non‑neoplastic) when immunophenotyping is clinically indicated.
Coding and reimbursement requirements
- Use CPT codes 88184–88189 for flow cytometric immunophenotyping for assessment of potential hematolymphoid neoplasia.
- Code 88184: first marker per specimen — reimbursable up to a maximum of 2 units per date of service.
- Code 88185: each additional marker — reimbursable up to a maximum of 35 units per date of service.
Limitations / exclusions
- Measurement of flow cytometry‑derived DNA content (DNA index) or cell proliferative activity (S‑phase fraction or % S‑phase) for prognostic or therapeutic purposes in routine clinical management of cancers does NOT meet coverage criteria.
- In patients with a neoplasm with an established immunophenotype, subsequent testing should be limited to diagnostically relevant markers only.
inv-02: Coverage stance on DNA ploidy / S‑phase
Professional society positions and guidance regarding DNA ploidy and S‑phase/cell cycle analysis:
inv-03: Acute leukemia—CAP/ASH recommendations
CAP/ASH joint guideline recommendations for use of flow cytometry in the initial workup of acute leukemia:
inv-04: Other indications and panel selection guidance
Additional endorsed clinical indications and guidance on reagent/panel selection:
Clinical indications supported by consensus or society guidance
- Flow cytometric analysis for inherited and acquired platelet disorders, including diagnosis of platelet glycoprotein deficiencies, alpha granule secretion defects, specific platelet activation pathway defects, platelet procoagulant activity disorders, pharmacodynamic monitoring of P2Y12 antagonists, and determination of immature platelet fraction (ISTH recommendations).
- Evaluation of cytopenias, elevated leukocyte counts, atypical cells or blasts, body fluids, plasmacytosis/monoclonal gammopathy, organomegaly and tissue masses, and selected patient monitoring indications (2006 Bethesda consensus).
Panel selection guidance
- Select initial reagent panels based on specimen type, clinical information, and cell morphology; initial panels typically include 4–12 reagents depending on indication (Bethesda consensus).
- Specific recommended markers: B cells (eg, CD5, CD10, CD19, CD20, CD45, kappa, lambda); T/NK cells (eg, CD2, CD3, CD4, CD5, CD7, CD8, CD45, CD56); myelomonocytic cells (eg, CD13, CD33, CD34, CD45, CD117, HLA‑DR); plasma cells (eg, CD19, CD38, CD45, CD56).
- Secondary/extended panels (when initial evaluation is inconclusive) may include larger reagent sets (5–23 reagents) tailored to the clinical question.
inv-05: Evidence-supported indications
Evidence base supporting flow cytometry clinical uses (selected references and guideline sources):
Evidence and guideline sources
- Systematic and observational studies have evaluated DNA ploidy and S‑phase fraction across tumor types (breast, endometrial, ovarian, gastrointestinal stromal tumors) with variable results; examples include Ross JS (1996), Mangili et al. (2008), Svanvik et al. (2019), and other observational reports.
- Multiple studies and reviews demonstrate utility of flow cytometry for hematologic diagnoses and monitoring, including diagnosis of classical Hodgkin lymphoma by flow cytometry, multiparameter assays for MRD detection in AML, and clonality testing for mature peripheral T‑cell lymphomas (Fromm et al.; Wang et al.; Novikov et al.; Paiva et al.).
- Professional society guidance informing clinical use includes CAP/ASH (initial acute leukemia workup), ERIC/ESCCA harmonisation for CLL diagnosis, Bethesda consensus recommendations for hematolymphoid neoplasia immunophenotyping, ISTH recommendations for platelet disorders, and NCCN guideline omission of S‑phase as a management tool for several solid tumors.
Indications Covered by Policy
inv-21: Immunophenotyping for hematologic disorders, immunodeficiency monitoring, transplant monitoring, and related conditions listed in the policy.
Covered immunophenotyping indications (flow cytometry) — clinical settings where testing meets coverage criteria:
Covered hematologic and related conditions
- Cytopenias with suspected hematologic malignancy.
- Lymphomas and leukemia (initial diagnosis and characterization).
- Myeloproliferative and lymphoproliferative disorders, and myelodysplastic syndromes.
- Plasma cell disorders and evaluation of plasmacytosis/monoclonal gammopathy (as part of immunophenotypic workup).
- Paroxysmal nocturnal hemoglobinuria (PNH).
- Mast cell neoplasms.
- Red cell and white cell non‑neoplastic disorders when immunophenotyping is clinically indicated.
Immunodeficiency and transplant monitoring
- B‑cell monitoring for immunosuppressive disorders.
- T‑cell monitoring for HIV/AIDS and related immunodeficiency evaluation.
- Preoperative and postoperative monitoring related to organ transplantation.
inv-22: Diagnosis and characterization of hematolymphoid neoplasms and related indications (acute leukemias, CLL, cytopenias with suspected malignancy, atypical cells/blasts, body fluids, plasma cell disorders, platelet disorders).
Diagnostic and characterization indications for hematolymphoid neoplasms and related specimen types:
Diagnostic indications
- Initial diagnosis and characterization of acute leukemias (AML, APL, B‑ALL, T‑ALL, ambiguous lineage) — panels sufficient to distinguish lineage as recommended by CAP/ASH.
- Diagnosis and characterization of chronic lymphocytic leukemia (CLL) with harmonized flow cytometry criteria (ERIC/ESCCA).
- Evaluation of cytopenias and atypical circulating cells/blasts to assess for hematolymphoid neoplasia (Bethesda consensus).
- Flow cytometry evaluation of body fluids (eg, CSF) in suspected/confirmed hematologic malignancy.
- Assessment of plasma cell disorders and detection of aberrant plasma cell immunophenotype.
Specimen and panel considerations
- Select reagent panels based on specimen type (peripheral blood, bone marrow, tissue, body fluid), clinical information, and morphologic findings; initial panels typically include 4–12 reagents with defined lineage markers (Bethesda recommendations).
- Use secondary/expanded panels (5–23 reagents) when the initial evaluation is inconclusive to further refine diagnosis and clonality.
inv-23: Diagnosis and monitoring of hematolymphoid neoplasia including clonality testing and minimal residual disease detection — supported by ERIC/ESCCA harmonization and CAP/ASH.
Flow cytometry for diagnosis and monitoring of hematolymphoid neoplasia, clonality testing, and MRD detection — criteria:
inv-24: DNA ploidy and S-phase fraction analysis for prognostic/response assessment in various solid tumors — multiple observational studies cited; guideline support varies.
DNA ploidy and S‑phase fraction testing — evidence and policy position:
inv-25: Assessment of primary immunodeficiencies and platelet function/number disorders via flow cytometry — supported by reviews and ISTH consensus.
Flow cytometry for immunodeficiency and platelet disorder assessment — supported uses:
Coding and Reimbursement Rules
| 88184 | Flow cytometry; first marker, per specimen |
| 88185 | Flow cytometry; each additional marker |
| 88187 | Flow cytometry code in series |
| 88188 | Flow cytometry code in series |
| 88189 | Flow cytometry code in series |
| 86355 | B cells, total count |
| 86357 | Natural killer (NK) cells, total count |
| 86359 | T cells; total count |
| 86360 | T cells; absolute CD4 and CD8 count, including ratio |
| 86361 | T cells; absolute CD4 count |
| 86355 | B cells, total count |
| 86356 | Mononuclear cell antigen, quantitative (eg, flow cytometry), not otherwise specified, each antigen |
| 86357 | Natural killer (NK) cells, total count |
| 86359 | T cells; total count |
| 86360 | T cells; absolute CD4 and CD8 count, including ratio |
| 86361 | T cells; absolute CD4 count |
| 88182 | Stem cells (ie, CD34), total count |
| (unspecified) | Flow cytometry, cell cycle or DNA analysis |
| 88185 | Flow cytometry, technical component only; each additional marker |
| 88187 | Flow cytometry, interpretation; 2 to 8 markers |
| No codes listed |
Provider Actions and Billing Guidance
Billing: correct CPT codes and unit/specimen limits for immunophenotyping
Use CPT codes 88184–88189 for flow cytometric immunophenotyping. Code 88184 must be billed for the first marker, per specimen, and is reimbursable up to a maximum of two units per date of service; code 88185 must be billed for each additional marker and is reimbursable up to a maximum of 35 units per date of service. Codes 88187–88189 are reimbursed at one unit per specimen, up to two specimens per date of service; do not use 88187–88189 together for a single specimen in any combination. Do not bill codes 88187–88189 in conjunction with codes 86355, 86356, 86357, 86359, 86360, 86361, or 86367. Use codes 86355, 86357, 86359, 86360, 86361, or 86367 for cell enumeration as single units only.
- 88184 = first marker, per specimen; reimbursable up to 2 units/DOS
- 88185 = each additional marker; reimbursable up to 35 units/DOS
- 88187–88189 = interpretation codes reimbursed 1 unit per specimen, up to 2 specimens/DOS; not to be combined together for one specimen
- 88187–88189 must not be billed with 86355/86356/86357/86359/86360/86361/86367
- Use 86355/86357/86359/86360/86361/86367 for cell enumeration (single unit only)
Regulatory/conflict resolution: follow government policies; LDTs regulated under CLIA
If this policy conflicts with an applicable government policy (for example, a Medicare LCD/NCD or a state Medicaid rule), the government policy governs the determination. Laboratory-developed tests (LDTs) are regulated by CMS under CLIA as high-complexity tests and are not FDA approved/cleared for clinical use.
- When conflict exists, follow the applicable LCD/NCD or state Medicaid policy.
- LDTs must be validated and are regulated under CLIA; FDA clearance/approval is not required for clinical use.
Guideline-influenced authorization: use professional society guidance when assessing clinical necessity
Clinical practice guidelines inform coverage and authorization decisions; references cited in the policy include CAP/ASH guidance for the initial diagnostic workup of acute leukemia, NCCN guidelines, ASCO tumor marker recommendations, and ISTH consensus documents that may influence what tests and panels are authorized.
- CAP/ASH initial diagnostic workup of acute leukemia (guides required panels and use in diagnosis/MRD assessment)
- NCCN clinical practice guidelines (inform tumor-type–specific use)
- ASCO tumor marker recommendations and ISTH consensus documents cited in the evidence base
Definitions
Frequency and Quantity Limits
Ordering Requirements
Confirm individual benefit coverage before ordering
Application of coverage criteria depends on the individual's benefit coverage at the time of the request; this policy does not specify additional provider-level ordering restrictions.
- Verify member benefit coverage prior to ordering
- No specific provider ordering restrictions are specified in this policy
Provide specimen type and clinical/morphologic information to guide panel selection
Selection of reagent panels and reagents for flow cytometry should be based on specimen type, clinical information, and cell morphology; ordering clinicians should provide relevant clinical and morphologic information to guide panel selection.
- Choose initial and secondary panels based on specimen (peripheral blood, bone marrow, tissue, body fluid) and clinical context
- Provide clinical history and morphology to support appropriate marker selection
No explicit ordering-provider restrictions in policy references
There are no explicit provider-type restrictions stated in the referenced guidelines; guideline-based diagnostic workup implies ordering by the treating clinicians (e.g., oncologists, hematologists, pathologists) but the policy does not impose specific ordering-provider limits.
- Guidelines inform appropriate ordering clinicians but do not impose explicit ordering-provider restrictions in this policy
- Order tests as part of guideline-directed diagnostic workup performed by treating clinicians
Services Not Covered
Flow cytometry-derived measures of DNA content (DNA Index) and cell proliferation (S‑phase fraction or % S‑phase) are not covered for prognostic or therapeutic decision‑making in the routine clinical management of cancer. The policy states that measurement of these parameters "DOES NOT MEET COVERAGE CRITERIA" because published scientific literature does not confirm that these tests are required and beneficial for diagnosis or treatment in this context.
Professional society guidance further supports this exclusion. ASCO concluded that flow cytometry–derived DNA ploidy and % S‑phase lack sufficient evidence for routine prognostic use—describing them as experimental or insufficient for early colorectal and breast cancer. The Bethesda (Clinical Cytometry Society) consensus also delineates clinical situations where flow cytometry is useful and explicitly lists conditions (eg, mature neutrophilia, polyclonal hypergammaglobulinemia, polycythemia, thrombocytosis, basophilia) in which flow cytometry is not indicated, reinforcing limited indications for DNA/ploidy applications.
Published studies cited in the evidence base report inconsistent prognostic value for DNA ploidy and S‑phase in certain tumor types. For example, research in endometrioid endometrial carcinoma found that DNA ploidy status, S‑phase fraction, and p53 were not independent prognostic factors for survival, illustrating contexts where these flow cytometry–derived metrics do not provide independent, actionable prognostic information and supporting the policy decision to treat routine clinical use as not meeting coverage criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.